top of page

BaxDuo Arctic Study

For Chronic Kidney Disease (CKD) and High Blood Pressure

About:

Arctic is a Phase III, Randomized, Double -Blind, Active-controlled Study to Assess the Efficacy, Safety and Tolerability of Baxdrostat in Combination with Dapagliflozin Compared with Dapagliflozin Alone on Chronic Kidney Disease (CKD) Progression in Participants with CKD and High Blood Pressure

​

Eligibility

You may be eligible for this study if you:

  • Are 18 years of age or older

  • Have been diagnosed with CKD

  • Have high blood pressure

​

**Other eligibility criteria will apply**

​

The investigational drug, study-related procedures, and doctor visits will be provided at no cost. If you travel to the site for your study visits, travel expenses may be reimbursed, and compensation for study-related time may be provided. 

If you’re interested in participating in one of our Research Studies:

Call 

303-232-3366

ext 2150, 2170 or 2190

bottom of page